Category: Market Commentary
Market Commentary

MedAvail Holdings, Inc. (MDVL) Stock Suring in Aftermarket, Here’s the Cause

MedAvail Holdings, Inc. (MDVL), a technology-enabled pharmacy company, has surged by 12% in aftermarket trading session and consequently is trading at $1.40 at the time of the writing. The increase has come in the wake of management changes in the company as well as the announcement of preliminary fourth-quarter 2021 and full year 2021 results. On Tuesday, MDVL closed the day at $1.25 after a slight increase of 0.81% during the mid-day session. Management Changes in MDVL In the late hours of Tuesday, MDVL announced that Mark Doerr, RPh has joined the company in the role of Chief Executive Officer. The appointment
Market Commentary

Veru Inc. (VERU) Stock Having Worthwhile Times in Aftermarket, Here’s the Reason

Veru Inc. (VERU), an oncology biopharmaceutical company, has gained an increase of 5.99% in aftermarket trading session. As a result, VERU stock is trading at $5.66 at the time of the writing. The increase could be attributed to the FDA grant of fast track designation for one of Veru’s products. On Monday, VERU closed the day at $5.34 after declining 2.20% during the regular trading session. Why VERU Increasing? On Monday, VERU announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to the Phase 3 registration program for the investigation of enobosarm. Enobosarm is a selective androgen
Market Commentary

NRX Pharmaceuticals, Inc. (NRXP) Stock Leaping Forward in Aftermarket, Here’s the Cause

NRX Pharmaceuticals, Inc. (NRXP), a clinical-stage small molecule pharmaceutical company, has soared by 6.85% in aftermarket trading session. Consequently, NRXP is trading at $4.99 at the time of the writing. The rise could be attributed to announcements regarding the company’s COVID-19 vaccine. On Friday, the stock closed the day at $4.67 after sliding 7.34% during the mid-day session. Why NRXP Surging? In the late hours of Friday, NRXP announced that its Chairman of the Board and Chief Executive Officer, Prof Jonathan Javitt, MD, MPH would present updates of the business of the company at the H.C. Wainwright BioConnect Virtual Confere. That includes

LBPS Stock
Market Commentary

Salarius Pharmaceuticals, Inc. (SLRX) Stock Declining Despite No Clear Reason

Salarius Pharmaceuticals, Inc. (SLRX), a clinical-stage biotechnology company, has declined by 1.76% in the premarket trading session. Consequently, SLRX stock s trading at $0.4793 at the time of the writing. On Thursday, SLRX closed the day at $0.49 after plunging 6.06% during the mid-day session. The last press release from the company was regarding a presentation at a virtual conference. Presentation at the Conferences On Thursday, SLRX announced that it would present at the upcoming H.C. Wainwright BioConnect. The company also said that it would participate in the Biotech Showcase and BIO Partnering @ JPM. All of these events will be held
Market Commentary

Context Therapeutics Inc. (CNTX) Stock Taking Solid Steps Forward, Here’s Why

Context Therapeutics Inc. (CNTX), a clinical-stage biopharmaceutical company, has increased by 3.61% in the premarket trading session. Consequently, CNTX stock is trading at $2.58 at the time of the writing. The increase could be attributed to the new appointments by the company. On Wednesday, CNTX closed the day at $2.49 after plunging 9.12% in the regular trading session. Why CNTX Rising? In the late hours of Wednesday, CNTX announced the appointment of Christopher Beck as SVP of Operations. Alongside him, Mark Fletcher, Ph.D. was appointed as VP of R&D. Besides, the company announced the planned retirement of the current head of

XOM Stock
Market Commentary

Annexon, Inc. (ANNX) Stock in Decline Despite of Positive Developments

Annexon, Inc. (ANNX), a clinical-stage biopharmaceutical company, has plunged 22.8% in aftermarket trading session. Consequently, the stock is trading at $8.5 at the time of the writing. On Tuesday, ANNX closed the day at $11.01 after sliding 7.79% during regular trading hours. The decline has come despite the announcement of positive interim phase 2 data. ANNX Reports Interim Data On Tuesday, ANNX announced the interim data from its ongoing and open-label phase 2 clinical trial of ANNX005. The trial was conducted in patients with Huntington’s disease who had competed for the treatment period of 24 weeks. The company is in the process
Market Commentary

WISeKey International Holding AG (WKEY) Stock Leaping Forward, Here’s the Reason

WISeKey International Holding AG (WKEY), a cybersecurity company, has surged 11.30% in aftermarket trading session. Consequently, WKEY stock is trading at $4.53 at the time of the writing. On Monday, WKEY gained an increase of 3.56% during the mid-day session and closed the day at $4.07. The increase in WKEY stock could potentially be attributed to the announcement of investment in Bitcoin mining. Why WKEY Rising? On Monday, WKEY announced that it intends to invest about $10 million over the next two years. The company would do this investment to perform Bitcoin mining. The investment is aimed to adopt cybersecurity technologies to

JNJ Stock
Market Commentary

Johnson & Johnson (JNJ) Stock Slightly Declined in Premarket Trading Session

Johnson & Johnson (JNJ), a company that researches and develops, manufactures, and sells a range of products in the health care field, has declined 0.13% in the premarket trading session. Consequently, JNJ stock is trading at $172.09 at the time of the writing. On Thursday, JNJ closed the day at $172.31 after a slight increase of 0.44% during the mid-day session. The last release from the company was regarding the efficiency of its vaccine against the Omicron variant of COVID-19. JNJ Announced Vaccine Efficiency Results On Thursday, JNJ announced the preliminary results from the South African Phase 3b Sisonke study. The results
Market Commentary

United Time Technology Co., Ltd. (UTME) Stock Declining After a Hefty Wednesday, Here’s the Reason

United Time Technology Co., Ltd. (UTME), a company that designs, develops, manufactures, and sells mobile phones, accessories, and related consumer electronics, has declined 9.44% in the premarket trading session. As a result, UTME stock is trading at $3.07 at the time of the writing. The decline could be attributed to the profit-taking factor after UTME closed Wednesday’s regular trading session on $3.39 after rocketing 47.39% during the day. The massive surge has come due to a buy signal by stock analysts which caused the investors to buy UTME stock in huge volumes. For the moment, let’s discuss some developments related
Market Commentary

Huntsman Corp. (HUN) Stock on a Slide, Here’s the Potential Cause

Huntsman Corp. (HUN), a company that manufactures and sells differentiated organic chemical products worldwide, has plunged 22.12% in aftermarket trading session. Consequently, HUN stock is trading at $26.20 at the time of the writing. The slide could potentially be attributed to the review of strategic options for the textile effect. On Tuesday, HUN closed the day at $33.64 after a slight increase of 0.18% during regular trading hours. Why HUN Plunging? On Tuesday, HUN announced a review of strategic options for its Textile Effects Division. Alongside that, it also announced a multi-year compensation plan designed to align the incentives of the

News IMC are non-trivial topics and publications about how you make money and properly dispose of it. We tell about business and entrepreneurship, start-ups, success stories. We also specialize in economic news.

Quick Links

Categories

©2024, Fueled by Smart TechOne